Company intelligence / Profile preview

ImmuONE

Milton Keynes, England, United Kingdomimmuone.com ↗

Ownership: Private
Development stage: Commercial

Overview

ImmuONE provides advanced human in vitro lung models—especially focusing on alveolar macrophages—to enable more accurate, ethical, and predictive inhalation safety testing for pharmaceuticals, chemicals, cosmetics, and related industries. Their technology helps clients assess pulmonary toxicity and immune responses without animal testing. The company’s morph_ONE™, ImmuPHAGE™, and ImmuLUNG™ platforms are used by industry partners to evaluate new compounds’ effects on human lung tissue at a preclinical stage.

Therapeutic areas: Pulmonology
Modalities: In vitro cell modelsHuman alveolar macrophage and epithelial cell culture systems
Industry: Non-Drug Biotech

Partnerships

Collaborates with pharmaceutical companies for contract research services; specific partners not disclosed publicly.

Beyond the preview

Go deeper on ImmuONE.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmuONE.

Explore the full profile